Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit
Abstract Introduction Despite the approval of a 20-valent pneumococcal conjugate vaccine (PCV20) for pediatric use in many regions globally, integration of PCV20 into national immunization programs (NIPs) is delayed in some countries. We explored the public health and economic benefits forfeited by...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-02-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-025-01108-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849392276310065152 |
|---|---|
| author | Johnna Perdrizet An Ta Liping Huang Warisa Wannaadisai Aleksandar Ilic Kyla Hayford Ayman Sabra |
| author_facet | Johnna Perdrizet An Ta Liping Huang Warisa Wannaadisai Aleksandar Ilic Kyla Hayford Ayman Sabra |
| author_sort | Johnna Perdrizet |
| collection | DOAJ |
| description | Abstract Introduction Despite the approval of a 20-valent pneumococcal conjugate vaccine (PCV20) for pediatric use in many regions globally, integration of PCV20 into national immunization programs (NIPs) is delayed in some countries. We explored the public health and economic benefits forfeited by postponing transitions from lower-valent pneumococcal conjugate vaccines (PCVs) to PCV20. Methods A targeted literature review (TLR) identified modeling studies comparing the public health and economic impact of PCV20 versus 13-valent PCV (PCV13) or 15-valent PCV (PCV15) in pediatric NIPs. Only studies with accessible models underwent data extraction and analysis. Foregone public health (pneumococcal disease cases/disease-related deaths) and economic (medical/non-medical costs) outcomes, defined as the projected incremental differences between the outcomes associated with PCV20 and lower-valent PCVs, were calculated over 2 years following PCV20 implementation (per year and month). Discount rates for all outcomes were adjusted to 0% given the short time horizon and for consistency across analyses. Results The TLR identified models from 13 countries globally. The monthly health benefits forgone due to delayed transitions from PCV13 to PCV20 ranged between 40 (Slovakia) and 1740 (Canada) pneumococcal disease cases averted in the first year of delay across populations, increasing by between 1.5 (Sweden) and 15–16 times (Germany and Mexico) in the second year. Forgone cumulative disease-related deaths averted ranged from 18 (Spain) to 2657 (Germany) and forgone cumulative direct medical cost-savings ranged from 930 thousand Euros (Portugal) to 146 million Euros (Germany) due to delayed transitions from PCV13 to PCV20 over 2 years. Similar, but slightly reduced, benefits were forfeited with delayed transitions from PCV15 to PCV20. Conclusion Delays in implementing PCV20 into pediatric NIPs were projected to have substantial negative public health and economic consequences. These results underscore the necessity for national immunization technical advisory groups, policymakers, health organizations, and manufacturers to accelerate replacement of lower-valent standard-of-care PCVs with PCV20. |
| format | Article |
| id | doaj-art-d146d3f2d4e54f89858ff6acdda210b8 |
| institution | Kabale University |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-d146d3f2d4e54f89858ff6acdda210b82025-08-20T03:40:48ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822025-02-0114350152510.1007/s40121-025-01108-3Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic BenefitJohnna Perdrizet0An TaLiping Huang1Warisa Wannaadisai2Aleksandar Ilic3Kyla Hayford4Ayman Sabra5Global Health Economics and Outcomes Research, Pfizer CanadaGlobal Health Economics and Outcomes Research, Pfizer IncGlobal Health Economics and Outcomes Research, Pfizer UKGlobal Health Economics and Outcomes Research, Pfizer UKMedial Development and Scientific/Clinical Affairs, Pfizer VaccinesMedical Affairs, Vaccines, Antivirals and Evidence Generation, PfizerAbstract Introduction Despite the approval of a 20-valent pneumococcal conjugate vaccine (PCV20) for pediatric use in many regions globally, integration of PCV20 into national immunization programs (NIPs) is delayed in some countries. We explored the public health and economic benefits forfeited by postponing transitions from lower-valent pneumococcal conjugate vaccines (PCVs) to PCV20. Methods A targeted literature review (TLR) identified modeling studies comparing the public health and economic impact of PCV20 versus 13-valent PCV (PCV13) or 15-valent PCV (PCV15) in pediatric NIPs. Only studies with accessible models underwent data extraction and analysis. Foregone public health (pneumococcal disease cases/disease-related deaths) and economic (medical/non-medical costs) outcomes, defined as the projected incremental differences between the outcomes associated with PCV20 and lower-valent PCVs, were calculated over 2 years following PCV20 implementation (per year and month). Discount rates for all outcomes were adjusted to 0% given the short time horizon and for consistency across analyses. Results The TLR identified models from 13 countries globally. The monthly health benefits forgone due to delayed transitions from PCV13 to PCV20 ranged between 40 (Slovakia) and 1740 (Canada) pneumococcal disease cases averted in the first year of delay across populations, increasing by between 1.5 (Sweden) and 15–16 times (Germany and Mexico) in the second year. Forgone cumulative disease-related deaths averted ranged from 18 (Spain) to 2657 (Germany) and forgone cumulative direct medical cost-savings ranged from 930 thousand Euros (Portugal) to 146 million Euros (Germany) due to delayed transitions from PCV13 to PCV20 over 2 years. Similar, but slightly reduced, benefits were forfeited with delayed transitions from PCV15 to PCV20. Conclusion Delays in implementing PCV20 into pediatric NIPs were projected to have substantial negative public health and economic consequences. These results underscore the necessity for national immunization technical advisory groups, policymakers, health organizations, and manufacturers to accelerate replacement of lower-valent standard-of-care PCVs with PCV20.https://doi.org/10.1007/s40121-025-01108-3Pneumococcal conjugate vaccinePneumococcal diseasePCV20PolicymakersPediatricNational immunization program |
| spellingShingle | Johnna Perdrizet An Ta Liping Huang Warisa Wannaadisai Aleksandar Ilic Kyla Hayford Ayman Sabra Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit Infectious Diseases and Therapy Pneumococcal conjugate vaccine Pneumococcal disease PCV20 Policymakers Pediatric National immunization program |
| title | Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit |
| title_full | Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit |
| title_fullStr | Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit |
| title_full_unstemmed | Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit |
| title_short | Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit |
| title_sort | delayed transition to 20 valent pneumococcal conjugate vaccine in pediatric national immunization programs forgone public health and economic benefit |
| topic | Pneumococcal conjugate vaccine Pneumococcal disease PCV20 Policymakers Pediatric National immunization program |
| url | https://doi.org/10.1007/s40121-025-01108-3 |
| work_keys_str_mv | AT johnnaperdrizet delayedtransitionto20valentpneumococcalconjugatevaccineinpediatricnationalimmunizationprogramsforgonepublichealthandeconomicbenefit AT anta delayedtransitionto20valentpneumococcalconjugatevaccineinpediatricnationalimmunizationprogramsforgonepublichealthandeconomicbenefit AT lipinghuang delayedtransitionto20valentpneumococcalconjugatevaccineinpediatricnationalimmunizationprogramsforgonepublichealthandeconomicbenefit AT warisawannaadisai delayedtransitionto20valentpneumococcalconjugatevaccineinpediatricnationalimmunizationprogramsforgonepublichealthandeconomicbenefit AT aleksandarilic delayedtransitionto20valentpneumococcalconjugatevaccineinpediatricnationalimmunizationprogramsforgonepublichealthandeconomicbenefit AT kylahayford delayedtransitionto20valentpneumococcalconjugatevaccineinpediatricnationalimmunizationprogramsforgonepublichealthandeconomicbenefit AT aymansabra delayedtransitionto20valentpneumococcalconjugatevaccineinpediatricnationalimmunizationprogramsforgonepublichealthandeconomicbenefit |